Piper Jaffray Starts BridgeBio Pharma (BBIO) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts BBIO Hot Sheet
Price: $69.37 +1.79%
Rating Summary:
25 Buy, 3 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 10 | Down: 17 | New: 18
Rating Summary:
25 Buy, 3 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 10 | Down: 17 | New: 18
Join SI Premium – FREE
Piper Jaffray analyst Tyler Van Buren initiates coverage on BridgeBio Pharma (NASDAQ: BBIO) with a Overweight rating and a price target of $50.00.
For an analyst ratings summary and ratings history on BridgeBio Pharma click here. For more ratings news on BridgeBio Pharma click here.
Shares of BridgeBio Pharma closed at $27.51 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Roth/MKM Starts Dianthus Therapeutics (DNTH) at Buy
- Truist Securities Starts Evergy (EVRG) at Buy
- Piper Sandler Assumes Delek US (DK) at Neutral
Create E-mail Alert Related Categories
Hot New Coverage, New CoverageRelated Entities
Piper JaffraySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
